| Item Type | Name |
|
Concept
|
Australia
|
|
Concept
|
Algorithms
|
|
Concept
|
Aging
|
|
Concept
|
Alleles
|
|
Concept
|
Amino Acid Sequence
|
|
Concept
|
Chromosomes, Human, Pair 11
|
|
Concept
|
Chromosomes, Human, Pair 2
|
|
Concept
|
Chromosomes, Human, Pair 6
|
|
Concept
|
Chromosomes, Human, Pair 8
|
|
Concept
|
Base Sequence
|
|
Concept
|
Biological Availability
|
|
Concept
|
Cell Count
|
|
Concept
|
Cell Differentiation
|
|
Concept
|
DNA Damage
|
|
Concept
|
Bacterial Proteins
|
|
Concept
|
Binding Sites
|
|
Concept
|
Blood Glucose
|
|
Concept
|
Drug Tolerance
|
|
Concept
|
Body Weight
|
|
Concept
|
Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing)
|
|
Concept
|
Cell Division
|
|
Concept
|
Brazil
|
|
Concept
|
Breast Feeding
|
|
Concept
|
Carbonated Beverages
|
|
Concept
|
Chromosomes, Bacterial
|
|
Concept
|
Chromosomes, Human, Pair 1
|
|
Concept
|
Chromosomes, Human, Pair 15
|
|
Concept
|
Chromosomes, Human, Pair 21
|
|
Concept
|
Chromosomes, Human, Pair 3
|
|
Concept
|
Chromosomes, Human, 4-5
|
|
Concept
|
Cell Transformation, Viral
|
|
Concept
|
Centrifugation, Density Gradient
|
|
Concept
|
Centromere
|
|
Concept
|
Cell Cycle
|
|
Concept
|
Chromosomes, Human, Pair 12
|
|
Concept
|
Chromosomes, Human, Pair 14
|
|
Concept
|
Chromosomes, Human, 6-12 and X
|
|
Concept
|
Child Development
|
|
Concept
|
Chromosome Deletion
|
|
Concept
|
Chromosomes, Human, Pair 13
|
|
Concept
|
Chromosomes, Human, Pair 22
|
|
Concept
|
Chromosomes, Human, Pair 4
|
|
Concept
|
Codon
|
|
Concept
|
Gastrointestinal Agents
|
|
Concept
|
Gastrointestinal Diseases
|
|
Concept
|
Genes, Immunoglobulin
|
|
Concept
|
Chromosomes, Human, Pair 5
|
|
Concept
|
Chromosomes, Human, Pair 7
|
|
Concept
|
Chromosomes, Human, 13-15
|
|
Concept
|
C-Reactive Protein
|
|
Concept
|
Glucosephosphate Dehydrogenase
|
|
Concept
|
Graft vs Host Disease
|
|
Concept
|
Chromosomes, Human, Pair 20
|
|
Concept
|
Chromosomes, Human, 16-18
|
|
Concept
|
Chromosomes, Human, 21-22 and Y
|
|
Concept
|
Hematocrit
|
|
Concept
|
Hematopoiesis
|
|
Concept
|
Homozygote
|
|
Concept
|
DNA-Binding Proteins
|
|
Concept
|
Dose-Response Relationship, Immunologic
|
|
Concept
|
Drug Synergism
|
|
Concept
|
Cytotoxicity, Immunologic
|
|
Concept
|
DNA Repair
|
|
Concept
|
Europe
|
|
Concept
|
Gene Frequency
|
|
Concept
|
Genes, Regulator
|
|
Concept
|
Genital Neoplasms, Male
|
|
Concept
|
Glucocorticoids
|
|
Concept
|
Glycoproteins
|
|
Concept
|
Graft Survival
|
|
Concept
|
London
|
|
Concept
|
Chromosomes, Human, Pair 17
|
|
Concept
|
Chromosomes, Human, Pair 9
|
|
Concept
|
Chromosomes, Human, 19-20
|
|
Concept
|
Exons
|
|
Concept
|
Drug Interactions
|
|
Concept
|
Drug Resistance
|
|
Concept
|
Chromosome Inversion
|
|
Concept
|
Microtubule-Associated Proteins
|
|
Concept
|
Gene Expression Regulation
|
|
Concept
|
Genes, Dominant
|
|
Concept
|
Genes
|
|
Concept
|
Glomerular Filtration Rate
|
|
Concept
|
Neoplasms, Radiation-Induced
|
|
Concept
|
Graft Rejection
|
|
Concept
|
Half-Life
|
|
Concept
|
Nucleic Acid Hybridization
|
|
Concept
|
Obesity
|
|
Concept
|
Oncogenes
|
|
Concept
|
Gingivitis
|
|
Concept
|
Health Planning Guidelines
|
|
Concept
|
DNA Replication
|
|
Concept
|
Dose-Response Relationship, Drug
|
|
Concept
|
Immune Tolerance
|
|
Concept
|
Erythropoiesis
|
|
Concept
|
Gene Amplification
|
|
Concept
|
Multigene Family
|
|
Concept
|
Glutathione
|
|
Concept
|
Granulocytes
|
|
Concept
|
Haploidy
|
|
Concept
|
Gastrointestinal Hemorrhage
|
|
Concept
|
Membrane Proteins
|
|
Concept
|
Lactation
|
|
Concept
|
Microfilament Proteins
|
|
Concept
|
Mitosis
|
|
Concept
|
Models, Genetic
|
|
Concept
|
Markov Chains
|
|
Concept
|
Pregnancy
|
|
Concept
|
Illinois
|
|
Concept
|
Immunoglobulin Variable Region
|
|
Concept
|
Optical Rotation
|
|
Concept
|
Molecular Sequence Data
|
|
Concept
|
Molecular Weight
|
|
Concept
|
Mutation
|
|
Concept
|
Philadelphia Chromosome
|
|
Concept
|
Nucleic Acid Conformation
|
|
Concept
|
Oxidation-Reduction
|
|
Concept
|
Sex Characteristics
|
|
Concept
|
Metaphase
|
|
Concept
|
Stimulation, Chemical
|
|
Concept
|
Phosphorylation
|
|
Concept
|
Polymorphism, Genetic
|
|
Concept
|
Feeding Behavior
|
|
Concept
|
Probability
|
|
Concept
|
Plasmids
|
|
Concept
|
Protein-Tyrosine Kinases
|
|
Concept
|
Protein Binding
|
|
Concept
|
Proto-Oncogene Proteins
|
|
Concept
|
Proteins
|
|
Concept
|
Genetic Markers
|
|
Concept
|
Histocompatibility
|
|
Concept
|
Radiation Injuries
|
|
Concept
|
Haplotypes
|
|
Concept
|
Repressor Proteins
|
|
Concept
|
Prothrombin Time
|
|
Concept
|
Radiation Tolerance
|
|
Concept
|
Interferon-gamma
|
|
Concept
|
Intestinal Absorption
|
|
Concept
|
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor
|
|
Concept
|
Genes, ras
|
|
Concept
|
Regulatory Sequences, Nucleic Acid
|
|
Concept
|
Polymorphism, Restriction Fragment Length
|
|
Concept
|
Risk
|
|
Concept
|
Sensitivity and Specificity
|
|
Concept
|
Singapore
|
|
Concept
|
Homeostasis
|
|
Concept
|
Leukemia, Radiation-Induced
|
|
Concept
|
Leukocyte Count
|
|
Concept
|
Body Mass Index
|
|
Concept
|
Time Factors
|
|
Concept
|
Transcription, Genetic
|
|
Concept
|
Transformation, Genetic
|
|
Concept
|
Genes, abl
|
|
Concept
|
United States
|
|
Concept
|
Trisomy
|
|
Concept
|
Practice Guidelines as Topic
|
|
Concept
|
Genetic Variation
|
|
Concept
|
Ultraviolet Rays
|
|
Concept
|
Germ-Line Mutation
|
|
Concept
|
Geriatric Assessment
|
|
Concept
|
Gene Rearrangement
|
|
Concept
|
Oncogene Proteins
|
|
Concept
|
Oncogene Proteins, Fusion
|
|
Concept
|
Trans-Activators
|
|
Concept
|
Gene Library
|
|
Concept
|
Drug Resistance, Neoplasm
|
|
Concept
|
Gene Duplication
|
|
Concept
|
S Phase
|
|
Concept
|
Genes, BRCA2
|
|
Concept
|
Up-Regulation
|
|
Concept
|
Southwestern United States
|
|
Concept
|
Genes, Tumor Suppressor
|
|
Concept
|
Genes, Wilms Tumor
|
|
Concept
|
Metabolic Clearance Rate
|
|
Concept
|
Immunocompromised Host
|
|
Concept
|
Ganciclovir
|
|
Concept
|
Gene Rearrangement, B-Lymphocyte, Heavy Chain
|
|
Concept
|
Chi-Square Distribution
|
|
Concept
|
Receptors, Granulocyte Colony-Stimulating Factor
|
|
Concept
|
Gene Expression
|
|
Concept
|
Proto-Oncogene Proteins c-myc
|
|
Concept
|
Hematopoietic Cell Growth Factors
|
|
Concept
|
Drugs, Generic
|
|
Concept
|
Proto-Oncogene Proteins c-abl
|
|
Concept
|
Methylation
|
|
Concept
|
North America
|
|
Concept
|
RNA-Binding Proteins
|
|
Concept
|
Point Mutation
|
|
Concept
|
Apoptosis
|
|
Concept
|
Gene Deletion
|
|
Concept
|
Sequence Deletion
|
|
Concept
|
Cell Proliferation
|
|
Concept
|
Inhibitor of Apoptosis Proteins
|
|
Concept
|
Fanconi Anemia Complementation Group D2 Protein
|
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
|
Concept
|
Mutation, Missense
|
|
Concept
|
Lymphocyte Count
|
|
Concept
|
Osteolysis
|
|
Concept
|
CpG Islands
|
|
Concept
|
Pentose Phosphate Pathway
|
|
Concept
|
Genetic Association Studies
|
|
Concept
|
Chromosomes, Artificial, Human
|
|
Concept
|
Ontario
|
|
Concept
|
Exome
|
|
Concept
|
Clonal Evolution
|
|
Concept
|
F-Box Proteins
|
|
Concept
|
Chromatin Assembly and Disassembly
|
|
Concept
|
Granulocyte Precursor Cells
|
|
Concept
|
Proto-Oncogene Proteins c-mdm2
|
|
Concept
|
Fanconi Anemia Complementation Group A Protein
|
|
Concept
|
Chromosomes, Artificial, Yeast
|
|
Concept
|
Proto-Oncogene Proteins c-bcl-2
|
|
Concept
|
Area Under Curve
|
|
Concept
|
Cell Cycle Proteins
|
|
Concept
|
Trinucleotide Repeats
|
|
Concept
|
Proto-Oncogene Proteins c-kit
|
|
Concept
|
Mitogen-Activated Protein Kinase Kinases
|
|
Concept
|
Genes, BRCA1
|
|
Concept
|
Catalytic Domain
|
|
Concept
|
Proto-Oncogene Proteins c-myb
|
|
Concept
|
Gene Expression Profiling
|
|
Concept
|
CCAAT-Enhancer-Binding Proteins
|
|
Concept
|
Platelet Count
|
|
Concept
|
Polyethylene Glycols
|
|
Concept
|
WT1 Proteins
|
|
Concept
|
Fanconi Anemia Complementation Group G Protein
|
|
Concept
|
Recombinant Proteins
|
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
|
Concept
|
Stem Cell Niche
|
|
Concept
|
Chimerism
|
|
Concept
|
Proto-Oncogene Proteins c-cbl
|
|
Concept
|
GATA1 Transcription Factor
|
|
Concept
|
Sister Chromatid Exchange
|
|
Concept
|
Stereoisomerism
|
|
Concept
|
Adaptor Proteins, Signal Transducing
|
|
Concept
|
Temperature
|
|
Concept
|
Protein Interaction Domains and Motifs
|
|
Concept
|
Down-Regulation
|
|
Concept
|
Genes, fms
|
|
Concept
|
Genes, myc
|
|
Concept
|
CD4-CD8 Ratio
|
|
Concept
|
Abnormal Karyotype
|
|
Concept
|
Gene Expression Regulation, Enzymologic
|
|
Concept
|
Gene Expression Regulation, Leukemic
|
|
Concept
|
LIM Domain Proteins
|
|
Concept
|
Fusion Proteins, bcr-abl
|
|
Concept
|
Genes, p53
|
|
Concept
|
Granulocyte Colony-Stimulating Factor
|
|
Concept
|
Proto-Oncogene Proteins p21(ras)
|
|
Concept
|
Zinc Fingers
|
|
Concept
|
DNA Methylation
|
|
Concept
|
GTP-Binding Proteins
|
|
Concept
|
Cell Dedifferentiation
|
|
Concept
|
Graft vs Leukemia Effect
|
|
Concept
|
Homeodomain Proteins
|
|
Concept
|
Drug Resistance, Multiple
|
|
Concept
|
Gene Dosage
|
|
Concept
|
Microsatellite Repeats
|
|
Concept
|
Cell Lineage
|
|
Concept
|
Ideal Body Weight
|
|
Concept
|
Tandem Repeat Sequences
|
|
Concept
|
Drug Resistance, Viral
|
|
Concept
|
Tumor Suppressor Proteins
|
|
Concept
|
Fanconi Anemia Complementation Group C Protein
|
|
Concept
|
Transcriptome
|
|
Concept
|
Karyotype
|
|
Concept
|
Genome-Wide Association Study
|
|
Concept
|
RNA-Binding Protein FUS
|
|
Concept
|
Tumor Microenvironment
|
|
Concept
|
Telomere Homeostasis
|
|
Concept
|
Suppressor of Cytokine Signaling Proteins
|
|
Concept
|
ZAP-70 Protein-Tyrosine Kinase
|
|
Concept
|
Myeloid-Lymphoid Leukemia Protein
|
|
Concept
|
Fanconi Anemia Complementation Group Proteins
|
|
Concept
|
Genes, Neoplasm
|
|
Concept
|
Diet, High-Fat
|
|
Concept
|
Neoplasm Grading
|
|
Concept
|
Blood Cell Count
|
|
Concept
|
Body Surface Area
|
|
Concept
|
Bone Resorption
|
|
Concept
|
Carrier Proteins
|
|
Concept
|
Cell Survival
|
|
Concept
|
Chromatin
|
|
Concept
|
Chromosome Aberrations
|
|
Concept
|
Chromosomes, Human
|
|
Concept
|
Chromosomes, Human, Pair 16
|
|
Concept
|
Genetic Testing
|
|
Concept
|
Genotype
|
|
Concept
|
Glucose
|
|
Concept
|
Heterozygote
|
|
Concept
|
Interphase
|
|
Concept
|
Kinetics
|
|
Concept
|
Genetic Linkage
|
|
Concept
|
Lymphocyte Activation
|
|
Concept
|
Monosomy
|
|
Concept
|
Neoplasm Proteins
|
|
Concept
|
Nuclear Proteins
|
|
Concept
|
Phenotype
|
|
Concept
|
Photolysis
|
|
Concept
|
Proto-Oncogenes
|
|
Concept
|
Recombinant Fusion Proteins
|
|
Concept
|
Translocation, Genetic
|
|
Concept
|
X Chromosome
|
|
Concept
|
Signal Transduction
|
|
Concept
|
Gene Expression Regulation, Neoplastic
|
|
Concept
|
Tumor Suppressor Protein p53
|
|
Concept
|
Granulocyte-Macrophage Colony-Stimulating Factor
|
|
Concept
|
Mutagenesis, Insertional
|
|
Concept
|
Polymorphism, Single-Stranded Conformational
|
|
Concept
|
Chromosome Breakage
|
|
Concept
|
Genetic Predisposition to Disease
|
|
Concept
|
Expressed Sequence Tags
|
|
Concept
|
Polymorphism, Single Nucleotide
|
|
Concept
|
Maximum Tolerated Dose
|
|
Concept
|
Genomics
|
|
Concept
|
Quantitative Trait Loci
|
|
Concept
|
Mammary Glands, Human
|
|
Concept
|
Epigenesis, Genetic
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Concept
|
Genes, Immunoglobulin Heavy Chain
|
|
Concept
|
Proto-Oncogene Proteins c-akt
|
|
Concept
|
Molecular Dynamics Simulation
|
|
Concept
|
Musculoskeletal Pain
|
|
Academic Article
|
Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient.
|
|
Academic Article
|
Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.
|
|
Academic Article
|
Acute myeloid leukaemia following interferon-alfa treatment of hairy cell leukaemia.
|
|
Academic Article
|
Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.
|
|
Academic Article
|
Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia.
|
|
Academic Article
|
Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases.
|
|
Academic Article
|
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
|
|
Academic Article
|
Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients.
|
|
Academic Article
|
Treatment of adult acute lymphoblastic leukemia.
|
|
Academic Article
|
Familial myeloid leukemia associated with loss of the long arm of chromosome 5.
|
|
Academic Article
|
Myeloid leukemia after hematotoxins.
|
|
Academic Article
|
Establishment and characterization of a megakaryoblast cell line with amplification of MLL.
|
|
Academic Article
|
Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia.
|
|
Academic Article
|
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience.
|
|
Academic Article
|
Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.
|
|
Academic Article
|
Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia.
|
|
Academic Article
|
Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map.
|
|
Academic Article
|
Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.
|
|
Academic Article
|
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
|
|
Academic Article
|
A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.
|
|
Academic Article
|
Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
|
|
Academic Article
|
dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
|
|
Academic Article
|
CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy.
|
|
Academic Article
|
Current use and future development of gemtuzumab ozogamicin.
|
|
Academic Article
|
Long-term follow-up of Cancer and Leukemia Group B studies in acute myeloid leukemia.
|
|
Academic Article
|
Pseudo-Gaucher histiocytes identified up to 1 year after transplantation for CML are BCR/ABL-positive.
|
|
Academic Article
|
Dose-intensive therapy for adult acute lymphoblastic leukemia.
|
|
Academic Article
|
A prospective pilot study to evaluate a new dental assessment and treatment paradigm for patients scheduled to undergo intensive chemotherapy for cancer.
|
|
Academic Article
|
Cancer and Leukemia Group B (CALGB) studies in adult acute lymhocytic leukemia.
|
|
Academic Article
|
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
|
|
Academic Article
|
Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364.
|
|
Academic Article
|
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.
|
|
Academic Article
|
Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia.
|
|
Academic Article
|
Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q).
|
|
Academic Article
|
New agents for induction and postremission therapy of acute myeloid leukemia.
|
|
Academic Article
|
MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia.
|
|
Academic Article
|
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
|
|
Academic Article
|
Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia.
|
|
Academic Article
|
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
|
|
Academic Article
|
t(1;3)(p36;p21) is a recurring therapy-related translocation.
|
|
Academic Article
|
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
|
|
Academic Article
|
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
|
|
Academic Article
|
Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).
|
|
Academic Article
|
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
|
|
Academic Article
|
Acute lymphoblastic leukaemia: diagnosis and classification.
|
|
Academic Article
|
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
|
|
Academic Article
|
Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia.
|
|
Academic Article
|
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
|
|
Academic Article
|
Polymorphisms in the MLL breakpoint cluster region (BCR).
|
|
Academic Article
|
Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B.
|
|
Academic Article
|
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
|
|
Academic Article
|
P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.
|
|
Academic Article
|
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
|
|
Academic Article
|
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
|
|
Academic Article
|
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
|
|
Academic Article
|
Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature.
|
|
Academic Article
|
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
|
|
Academic Article
|
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.
|
|
Academic Article
|
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
|
|
Academic Article
|
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
|
|
Academic Article
|
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
|
|
Academic Article
|
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.
|
|
Academic Article
|
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
|
|
Academic Article
|
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
|
|
Academic Article
|
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies.
|
|
Academic Article
|
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
|
|
Academic Article
|
Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.
|
|
Academic Article
|
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
|
|
Academic Article
|
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
|
|
Academic Article
|
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
|
|
Academic Article
|
Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
|
|
Academic Article
|
Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia.
|
|
Academic Article
|
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
|
|
Academic Article
|
Gene expression profiles in acute myeloid leukemia with common translocations using SAGE.
|
|
Academic Article
|
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
|
|
Academic Article
|
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
|
|
Academic Article
|
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
|
|
Academic Article
|
Deletions of interferon genes in acute lymphoblastic leukemia.
|
|
Academic Article
|
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
|
|
Academic Article
|
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
|
|
Academic Article
|
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
|
|
Academic Article
|
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
|
|
Academic Article
|
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
|
|
Academic Article
|
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).
|
|
Academic Article
|
Therapy-related myeloid leukemia.
|
|
Academic Article
|
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
|
|
Academic Article
|
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11).
|
|
Academic Article
|
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia.
|
|
Academic Article
|
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations.
|
|
Academic Article
|
Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.
|
|
Academic Article
|
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.
|
|
Academic Article
|
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.
|
|
Academic Article
|
Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
|
|
Academic Article
|
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
|
Academic Article
|
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
|
|
Academic Article
|
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.
|
|
Academic Article
|
Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in CML.
|
|
Academic Article
|
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
|
|
Academic Article
|
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
|
|
Academic Article
|
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
|
|
Academic Article
|
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
|
|
Academic Article
|
The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma.
|
|
Academic Article
|
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Acute lymphoblastic leukemia: older patients and newer drugs.
|
|
Academic Article
|
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review.
|
|
Academic Article
|
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
|
|
Academic Article
|
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
|
|
Academic Article
|
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
|
|
Academic Article
|
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
|
|
Academic Article
|
Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia.
|
|
Academic Article
|
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
|
|
Academic Article
|
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
|
|
Academic Article
|
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
|
|
Academic Article
|
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
|
|
Academic Article
|
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Clinicopathologic manifestations and breakpoints of the t(3;5) in patients with acute nonlymphocytic leukemia.
|
|
Academic Article
|
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
|
|
Academic Article
|
MicroRNA expression in cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
|
Academic Article
|
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
|
|
Academic Article
|
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.
|
|
Academic Article
|
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?
|
|
Academic Article
|
The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
|
|
Academic Article
|
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
|
|
Academic Article
|
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
|
|
Academic Article
|
Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm.
|
|
Academic Article
|
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.
|
|
Academic Article
|
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
|
|
Academic Article
|
MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
|
|
Academic Article
|
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
|
|
Academic Article
|
Acute leukemia occurring after radiotherapy and chemotherapy with a nitrosourea, PCNU.
|
|
Academic Article
|
Gemtuzumab ozogamicin: time to resurrect?
|
|
Academic Article
|
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.
|
|
Academic Article
|
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis.
|
|
Academic Article
|
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
|
|
Academic Article
|
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
|
|
Academic Article
|
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II.
|
|
Academic Article
|
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
|
|
Academic Article
|
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
|
|
Academic Article
|
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
|
|
Academic Article
|
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.
|
|
Academic Article
|
Association of a chromosomal 3;21 translocation with the blast phase of chronic myelogenous leukemia.
|
|
Academic Article
|
Assignment of the GM-CSF, CSF-1, and FMS genes to human chromosome 5 provides evidence for linkage of a family of genes regulating hematopoiesis and for their involvement in the deletion (5q) in myeloid disorders.
|
|
Academic Article
|
Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia.
|
|
Academic Article
|
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Cholesterol and mevalonic acid are independent requirements for the in vitro proliferation of human bone marrow granulocyte progenitor cells: studies using ML-236B.
|
|
Academic Article
|
Der(5)t(5;7)(q11.2;p11.2): a new recurring abnormality in malignant myeloid disorders.
|
|
Academic Article
|
Acute myelomonocytic leukemia with abnormal eosinophils presenting as an ovarian mass: a report of two cases and a review of the literature.
|
|
Academic Article
|
Assignment of CSF-1 to 5q33.1: evidence for clustering of genes regulating hematopoiesis and for their involvement in the deletion of the long arm of chromosome 5 in myeloid disorders.
|
|
Academic Article
|
Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission.
|
|
Academic Article
|
Genetic pathways leading to therapy-related myeloid neoplasms.
|
|
Academic Article
|
Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemias with a del(5q).
|
|
Academic Article
|
The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982).
|
|
Academic Article
|
The DNA synthetic response of normal and abnormal human lymphocytes to mevalonic acid: the role of granulocytes as a helper population.
|
|
Academic Article
|
Complex rearrangement of the T cell receptor in large granular lymphocytosis associated with myeloid suppression.
|
|
Academic Article
|
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
|
|
Academic Article
|
Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia.
|
|
Academic Article
|
Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study.
|
|
Academic Article
|
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
|
|
Academic Article
|
The relationship of the in vivo cell cycle characteristics and treatment outcome in acute myelogenous leukemia to the expression of the FMS and MYC proto-oncogenes.
|
|
Academic Article
|
Psychosocial symptomatology, personal growth, and development among young adult patients following the diagnosis of leukemia or lymphoma.
|
|
Academic Article
|
Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study.
|
|
Academic Article
|
Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders.
|
|
Academic Article
|
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
|
|
Academic Article
|
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.
|
|
Academic Article
|
Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia.
|
|
Academic Article
|
Effects of rhGM-CSF on myeloid clonogenic cells in acute myelogenous leukemia patients.
|
|
Academic Article
|
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
|
|
Academic Article
|
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.
|
|
Academic Article
|
Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings.
|
|
Academic Article
|
Use of decline in D-xylose absorption to predict infection following intensive chemotherapy.
|
|
Academic Article
|
Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility.
|
|
Academic Article
|
Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia.
|
|
Academic Article
|
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
|
|
Academic Article
|
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
|
|
Academic Article
|
Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion.
|
|
Academic Article
|
The serial study of c-myc expression in bone marrow biopsy specimens during treatment for acute myelogenous leukaemia.
|
|
Academic Article
|
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.
|
|
Academic Article
|
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
|
|
Academic Article
|
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
|
|
Academic Article
|
A recurring chromosome rearrangement, dic(16;22), in acute nonlymphocytic leukemia.
|
|
Academic Article
|
Chromosome changes in hematologic malignancies.
|
|
Academic Article
|
c-myc and c-myb expression in acute myelogenous leukemia.
|
|
Academic Article
|
Establishment of a leukemia cell line with i(12p) from a patient with a mediastinal germ cell tumor and acute lymphoblastic leukemia.
|
|
Academic Article
|
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.
|
|
Academic Article
|
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.
|
|
Academic Article
|
Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B.
|
|
Academic Article
|
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
|
|
Academic Article
|
Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP.
|
|
Academic Article
|
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
|
|
Academic Article
|
Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia.
|
|
Academic Article
|
Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop.
|
|
Academic Article
|
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
|
|
Academic Article
|
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
|
|
Academic Article
|
RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
|
|
Academic Article
|
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.
|
|
Academic Article
|
G3139, a BCL-2 antisense oligo-nucleotide, in AML.
|
|
Academic Article
|
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
|
|
Academic Article
|
Adult ALL: where are we and where are we going?
|
|
Academic Article
|
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
|
|
Academic Article
|
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
|
|
Academic Article
|
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
|
|
Academic Article
|
t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia.
|
|
Academic Article
|
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Therapy-related myeloid sarcoma with an NPM1 mutation.
|
|
Academic Article
|
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.
|
|
Academic Article
|
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
|
|
Academic Article
|
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.
|
|
Academic Article
|
Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
|
|
Academic Article
|
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
|
|
Academic Article
|
'Golden tongue' syndrome caused by Ramichloridium schulzeri.
|
|
Academic Article
|
Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma.
|
|
Academic Article
|
Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo.
|
|
Academic Article
|
Studies of the human c-myb gene and its product in human acute leukemias.
|
|
Academic Article
|
Leiomyosarcoma of the scrotum in a man who had received scrotal irradiation as a child.
|
|
Academic Article
|
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
|
|
Academic Article
|
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
|
|
Academic Article
|
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
|
|
Academic Article
|
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
|
|
Academic Article
|
Immune reconstitution after combined haploidentical and umbilical cord blood transplant.
|
|
Academic Article
|
Current practices in the management of chronic myeloid leukemia.
|
|
Academic Article
|
Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia.
|
|
Academic Article
|
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.
|
|
Academic Article
|
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
|
|
Academic Article
|
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
|
|
Academic Article
|
Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.
|
|
Academic Article
|
miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.
|
|
Academic Article
|
The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q).
|
|
Academic Article
|
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
|
|
Academic Article
|
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
|
|
Academic Article
|
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
|
|
Academic Article
|
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
|
|
Academic Article
|
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.
|
|
Academic Article
|
Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays.
|
|
Academic Article
|
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
|
|
Academic Article
|
Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification.
|
|
Academic Article
|
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
|
|
Academic Article
|
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
|
|
Academic Article
|
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
|
|
Academic Article
|
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
|
|
Academic Article
|
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
|
|
Academic Article
|
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
|
|
Academic Article
|
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.
|
|
Academic Article
|
The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment.
|
|
Academic Article
|
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
|
|
Academic Article
|
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance).
|
|
Academic Article
|
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.
|
|
Academic Article
|
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
|
|
Academic Article
|
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
|
|
Academic Article
|
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.
|
|
Academic Article
|
Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma.
|
|
Academic Article
|
Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study.
|
|
Academic Article
|
Overexpression and knockout of miR-126 both promote leukemogenesis.
|
|
Academic Article
|
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
|
|
Academic Article
|
Is there a best TKI for chronic phase CML?
|
|
Academic Article
|
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
|
|
Academic Article
|
Is there a best TKI for chronic phase CML?
|
|
Academic Article
|
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.
|
|
Academic Article
|
Transformation of chlorinated aliphatic compounds by ferruginous smectite.
|
|
Academic Article
|
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
|
|
Academic Article
|
Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy.
|
|
Academic Article
|
Positron Emission Tomography-Computed Tomography Imaging of a Patient With Several Myeloid Sarcomas With FLT3-ITD and NPM1 Mutations.
|
|
Academic Article
|
miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia.
|
|
Academic Article
|
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
|
|
Academic Article
|
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
|
|
Academic Article
|
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.
|
|
Academic Article
|
Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment.
|
|
Academic Article
|
Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles.
|
|
Academic Article
|
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
|
|
Academic Article
|
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
|
|
Academic Article
|
Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism.
|
|
Academic Article
|
Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host.
|
|
Academic Article
|
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).
|
|
Academic Article
|
An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.
|
|
Academic Article
|
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
|
|
Academic Article
|
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.
|
|
Academic Article
|
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.
|
|
Academic Article
|
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase.
|
|
Academic Article
|
Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy.
|
|
Academic Article
|
ATP-binding cassette (ABC) proteins in untreated acute myeloid leukemia (AML) in patients 60 years and older (CALGB 9760).
|
|
Academic Article
|
Patients (pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC) intensification: A Cancer and Leukemia Group B (CALGB) study.
|
|
Academic Article
|
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
|
|
Academic Article
|
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
|
|
Academic Article
|
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
|
|
Academic Article
|
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
|
|
Academic Article
|
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
|
|
Academic Article
|
RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia.
|
|
Academic Article
|
Treatment of Acute Promyelocytic Leukemia in Adults.
|
|
Academic Article
|
Cu(II) sensitizes pBR322 plasmid DNA to inactivation by UV-B (280-315 nm).
|
|
Academic Article
|
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
|
|
Academic Article
|
Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).
|
|
Academic Article
|
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
|
|
Academic Article
|
Imatinib is still recommended for frontline therapy for CML.
|
|
Academic Article
|
Patients' perspectives on the definition of cure in chronic myeloid leukemia.
|
|
Academic Article
|
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.
|
|
Academic Article
|
Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance).
|
|
Academic Article
|
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
|
|
Academic Article
|
Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial.
|
|
Academic Article
|
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.
|
|
Academic Article
|
Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
|
|
Academic Article
|
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.
|
|
Academic Article
|
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
|
|
Academic Article
|
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.
|
|
Academic Article
|
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation.
|
|
Academic Article
|
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
|
|
Academic Article
|
Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force.
|
|
Academic Article
|
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
|
|
Academic Article
|
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
|
|
Academic Article
|
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.
|
|
Academic Article
|
Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy.
|
|
Academic Article
|
Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy.
|
|
Academic Article
|
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
|
|
Academic Article
|
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
|
|
Academic Article
|
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
|
|
Academic Article
|
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101.
|
|
Academic Article
|
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
|
|
Academic Article
|
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
|
|
Academic Article
|
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
|
|
Academic Article
|
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
|
|
Academic Article
|
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
|
|
Academic Article
|
High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.
|
|
Academic Article
|
Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasms.
|
|
Academic Article
|
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors.
|
|
Academic Article
|
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study.
|
|
Academic Article
|
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
|
|
Academic Article
|
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
|
|
Academic Article
|
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.
|
|
Academic Article
|
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
|
|
Concept
|
Pharmacogenomic Variants
|
|
Concept
|
MDS1 and EVI1 Complex Locus Protein
|
|
Concept
|
Myeloid Ecotropic Viral Integration Site 1 Protein
|
|
Concept
|
RUNX1 Translocation Partner 1 Protein
|
|
Concept
|
Pediatric Obesity
|
|
Concept
|
Ataxia Telangiectasia Mutated Proteins
|
|
Academic Article
|
High-fat diet, but not duration of lactation, increases mammary gland lymphatic vessel function and subsequent growth of inflammatory breast cancer cells.
|
|
Academic Article
|
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
|
|
Academic Article
|
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
|